KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy. We also explored the role of excision repair cross complementing group-1 (ERCC-1). METHODS: Ninety anti-epidermal growth factor receptor-naive advanced colorectal ca...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Basso, M, Strippoli, A, Orlandi, A, Martini, M, Calegari, M A, Schinzari, G, Di Salvatore, M, Cenci, T, Cassano, A, Larocca, L M, Barone, C
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2013
Fag:
Molecular Diagnostics
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553525/
https://ncbi.nlm.nih.gov/pubmed/23175150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.526
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker